| Tumor-suppressive effects of 1,25-dihydroxyvitamin D3 in gastric cancer cells. | |
| | |
MedLine Citation:
|
PMID: 23298900 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
It has been previously demonstrated that vitamin D acts as a prognostic indicator of gastric cancer and may be correlated with the incidence risk of gastric cancer. However, the effect of 1,25-dihydroxyvitamin D3 on the apoptosis of human gastric cancer cells is unclear. The aim of this study was to determine whether 1,25-dihydroxyvitamin D3 induced the cellular apoptosis of BGC-823 gastric cancer cells and to determine the potential mechanism of action. We demonstrate that 1,25-dihydroxyvitamin D3 induced the apoptosis of gastric cancer cells via the processing of PARP and cleavage of caspase 3. Additionally, an increase in BAX expression and a decrease in ERK1/2 and AKT phosphorylation were associated with 1,25-dihydroxyvitamin D3-induced apoptosis. The mRNA expression levels of VDR, CYP24A1, and p21 were increased significantly following 1,25-dihydroxyvitamin D3 treatment. These findings suggest that 1,25-dihydroxyvitamin D3 exerts tumor-suppressive effects on BGC-823 human gastric cancer cells. |
| | |
Authors:
|
Anyu Bao; Yan Li; Yongqing Tong; Hongyun Zheng; Wei Wu; Chuandong Wei |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-9 |
Journal Detail:
|
Title: Hepato-gastroenterology Volume: 60 ISSN: 0172-6390 ISO Abbreviation: Hepatogastroenterology Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8007849 Medline TA: Hepatogastroenterology Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Factors affecting transient urinary retention after transobturator tape mid-urethral sling surgery f...
Next Document: RCan Primary LDLT be the Alternative First Line Treatment for Infant Patients with Biliary Atresia?